Acute myocarditis after COVID-19 vaccination

Saadi, Sufana M; Bossei, Asseil A; Alsulimani, Loui K.

doi:10.15537/smj.2022.43.11.20220292

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6]. Only few isolated case reports were published from Saudi Arabia so far [14,15]. The objective of the current report was to describe the clinical presentation, management, and outcomes of patients who developed myocarditis, pericarditis, or myopericarditis following the administration of COVID-19 vaccination in a large specialized cardiac center.…”

Section: Introductionmentioning

confidence: 99%

Myocarditis and Pericarditis Following the COVID-19 Vaccination: A Single-Centre Case Seriese

Alshugair,

Helali,

Almousa

et al. 2024

Preprint

View full text Add to dashboard Cite

The Surveillance of rare adverse events following vaccination, particularly related to COVID-19 vaccines, requires thorough examination. This paper investigates vaccine-associated myocarditis and/or pericarditis (VAMPS), presenting insights into clinical manifestations, management, and outcomes. Conducted at the Prince Sultan Cardiac Center in Saudi Arabia from March 2021 to May 2022, this retrospective case series comprises 20 patients with an average age of 27.9 ± 14.0 years, predominantly males (70%). Pfizer-BioNTech, AstraZeneca, and Moderna vaccines were administered in 74%, 21%, and 5% of cases, respectively, with 53% receiving the second dose, 26% the booster, and 21% the initial dose. Common symptoms included shortness of breath (60%), chest pain (50%), palpitations (40%), premature ventricular contractions (35%), and fever (25%). Cardiac magnetic resonance imaging revealed preserved left ventricular function (80%), subepicardial and/or mid-wall late gadolinium enhancement (65%), and lateral (39%), anterolateral (15%), inferolateral (15%), and anteroseptal (15%) segments affected. Myocarditis, pericarditis, and myopericarditis were diagnosed in 40%, 20%, and 40% of cases, respectively. C-reactive protein was elevated in two-thirds of patients. Recovery was achieved with anti-inflammatory medications, primarily colchicine (72%), aspirin(39%), and ibuprofen (33%). While no fatalities occurred, 30% experienced severe complications, and 15% had minor complications. In conclusion, VAMPS exhibits distinct characteristics and may lead to serious complications. Cardiologists should consider VAMPS in the differential diagnosis for symptomatic patients recently vaccinated against COVID-19, emphasizing the importance of ongoing surveillance and understanding of rare adverse events.

show abstract

Section: Introductionmentioning

confidence: 99%

Myocarditis and Pericarditis Following the COVID-19 Vaccination: A Single-Centre Case Seriese

Alshugair,

Helali,

Almousa

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Elasomeran

2023

Reactions Weekly

View full text Add to dashboard Cite

Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine

Badaró

Novaes

Andrade³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

A 23-year-old man started with chest pain 8 h after his first Pfizer-BioNTech COVID-19 vaccination. ECG evaluation showed sinus tachycardia with ST-segment elevation in D1, AVL, V5, and V6, the findings compatible with acute subepicardial myocardial damage. However, cardiac MRI documented myocardial fibrosis, with cardiac late enhancement non-ischemic pattern with diffuse edema. He had no other symptoms to suggest another etiology than the vaccination. The patient was hospitalized and received corticosteroid (prednisolone) daily. Then, 2 weeks after hospitalization, all laboratory parameters and ECG were normal and the patient was discharged from the hospital. The patient had a history of Wolf-Parkinson White that was corrected with ablation when he was 11 years old. This report calls attention to myocardial adverse reaction risk for mRNA COVID-19 vaccines for people with a previous cardiac disease history.

show abstract

Acute myocarditis after COVID-19 vaccination

Cited by 3 publications

References 9 publications

Myocarditis and Pericarditis Following the COVID-19 Vaccination: A Single-Centre Case Seriese

Myocarditis and Pericarditis Following the COVID-19 Vaccination: A Single-Centre Case Seriese

Elasomeran

Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine

Contact Info

Product

Resources

About